Sinapis Pharma is a Jacksonville, Florida-based developer of a novel therapeutic approach to neuronal protection using an intravenous methamphetamine technology. The company reports strong pre-clinical data in stroke and traumatic brain injury animal models, demonstrating a 12-hour therapeutic window and multiple-pathway neuroprotection. It completed an undisclosed bridge financing to continue supporting its drug development program. The financing will enable the company to conduct a Phase I pharmacokinetic and safety trial in humans, with trial completion anticipated in Q3 2010. Sinapis anticipates agreeing on a Phase II proof-of-concept study protocol with the FDA in late 2010. The company plans to initiate the Phase II trial in early 2011. Sinapis Pharma is a Jacksonville, Florida-based early-stage biotechnology company developing an intravenous methamphetamine therapeutic for neuronal protection. Its lead compound, methamphetamine, has shown strong pre-clinical efficacy in stroke and traumatic brain injury models. Preclinical data reportedly demonstrate a 12-hour therapeutic window and multi-pathway neuroprotection. The company describes a novel therapeutic approach to neuronal protection using its IV methamphetamine technology. The $510,000 Series A raise will fund advancement to regulatory and clinical milestones, including an IND submission and first-in-human trials.

Total raised

$1M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2009